Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 144 KB, PDF-dokument
Inactivating mutations in Bruton's tyrosine kinase (BTK) in patients with follicular lymphoma (FL) have recently been reported. These mutations were found in BTK inhibitor-treatment naïve patients. Here, we report the BTK mutation status in a real-world cohort of patients with non-Hodgkin lymphoma. We found primary BTK mutations in 7.7% of patients with large B-cell lymphoma (LBCL) and in 14.1% of patients with FL. All patients with BTK-mutated LBCL were BCL2 translocation positive, and the correlation between BCL2 translocation and BTK mutation persisted even when patients with known transformation from FL were excluded.
Originalsprog | Engelsk |
---|---|
Tidsskrift | eJHaem |
Vol/bind | 3 |
Udgave nummer | 3 |
Sider (fra-til) | 936-939 |
Antal sider | 4 |
ISSN | 2688-6146 |
DOI | |
Status | Udgivet - 2022 |
Bibliografisk note
© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
ID: 345683026